Spending bill passed by the House gives NIH $415M raise, NCI gets $128M Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

The White House last week considered, but ultimately abandoned, a plan to create a panel that would review NIH grants in an effort to weed out projects the administration regards as “woke.”

HHS issues direct final rule to reduce reliance on animal testing

FDA has issued a direct final rule that changes the language in its regulations so that “animal testing” is no longer described as the default or defining form of “nonclinical” safety testing.

September 25, 2026

Vol.52 No.35

By Claire Marie Porter

In Brief

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.

September 18, 2026

Vol.52 No.34

In Brief

VCU Massey researchers receive $2.5M NIH grant for targeted therapy for breast, pancreatic cancer

Researchers at VCU Massey Comprehensive Cancer Center were recently awarded a $2.5 million R01 grant from NCI. The five-year grant will allow Massey to evaluate the efficacy of TROP2 targeted antibody-drug conjugates to further enhance therapeutic benefits in both breast and pancreatic cancer care.

September 18, 2026

Vol.52 No.34

Cancer Policy

Federal judge declines to block Medicaid work requirements

The Centers for Medicare & Medicaid Services will move forward with its definition of “medically frail” that cancer patients and survivors on Medicaid will need to meet in order to earn an exemption from new work requirements.

HHS releases government-wide policy to prohibit gain-of-function research

The Trump Administration has released a new United States Government Policy for Stopping High-Risk Life Sciences Research, a framework that prohibits federally supported dangerous gain-of-function research while establishing stronger oversight for life sciences research that could pose significant risks to public health, biosecurity, or national security.

July 31, 2026

Vol.52 No.30

By Claire Marie Porter

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M

Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

YOU MAY BE INTERESTED IN

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

HHS issues direct final rule to reduce reliance on animal testing

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

VCU Massey researchers receive $2.5M NIH grant for targeted therapy for breast, pancreatic cancer

Federal judge declines to block Medicaid work requirements

HHS releases government-wide policy to prohibit gain-of-function research

Renew today!

Subscriber content

Never miss an issue!

Login